新光药业：股东和丰投资拟减持不超过3%股份

Core Viewpoint - Shengkang Pharmaceutical announced that its shareholder, Shengzhou Hefeng Investment Co., Ltd., which holds 15.74% of the shares, plans to reduce its holdings by up to 4.8 million shares, representing 3% of the total share capital, within a specified period from November 28, 2025, to February 27, 2026 [1] Summary by Category - Shareholder Reduction Plan - The shareholder intends to reduce its stake through two methods: a maximum of 1.6 million shares (1% of total share capital) via centralized bidding and up to 3.2 million shares (2% of total share capital) through block trading [1] - Timeline and Conditions - The reduction will take place within three months starting from November 28, 2025, and ending on February 27, 2026 [1] - Source of Shares - The shares to be reduced are sourced from pre-IPO holdings and capital reserve fund transfers [1]